MOTS-C before & after.

MOTS-C before and after: the changes actually measured

MOTS-C research has measured changes over hours, days and weeks, but those time frames describe different experiments. In ten healthy young men, exercise increased naturally occurring muscle MOTS-C to 11.9 times baseline. No peptide was administered to produce that result. [1]

Human exercise response, not an injection result or a percentage improvement in performance.

Treatment experiments in mice have also measured running distance, glucose handling and muscle retention. These are useful results with specific comparison groups. They do not supply a human weight-loss photograph, a predictable number of pounds lost or a guaranteed timeline for feeling more energetic.

The clearest way to read a result is to keep four details together: what changed, who was studied, what intervention they received and when the outcome was measured. A large number without those details can describe something very different from the benefit a reader expects.

The human exercise response: during a workout to four hours later

Blood and muscle followed different timelines. In the exercise study, circulating MOTS-C rose during and after the workout, then returned to baseline by four hours. Muscle levels remained elevated at that last measurement, while trending back toward baseline. [1]

A fold change describes the final value relative to the starting value. A level of 1.6 times baseline is a 60% increase. A level of 11.9 times baseline is a 1,090% increase. Neither calculation describes an increase in stamina, strength or the amount of peptide someone should administer.

The four-hour observation also is not an injected-drug half-life. It describes the changing concentration of an endogenous signal after exercise. A duration of benefit, an absorption curve and a repeat-administration interval require different measurements.

Why the same percentage should not be expected after every workout

Another human exercise study found a more modest pattern. Thirty participants were assigned to endurance exercise, resistance exercise or control. Blood and muscle were sampled before and after the sessions. The MOTS-C blood response after endurance exercise was a nonsignificant trend, and muscle MOTS-C did not change significantly. [2]

That study also measured humanin, a different mitochondrial-derived peptide. Its significant increase should not be relabelled as a MOTS-C result. Similar-sounding compounds in the same paper still have separate measurements and conclusions.

The studies used different exercise protocols and measurement approaches. Their findings show why one exercise response cannot become a universal target blood level. They also leave open whether a change in the measured peptide is a cause of adaptation, a response to it or part of a larger signaling process.

For a reader considering treatment, the important distinction is straightforward: observing a natural response helps explain the biology; demonstrating a benefit from an administered product requires a treatment comparison.

Animal treatment results and their time frames

A two-week mouse result does not establish a two-week human cycle. The species, route, dose, starting health and test conditions all form part of the experiment. Moving only the number of days into a consumer schedule would discard the information needed to interpret it.

These comparisons also are not all “before and after” measurements in the same subject. Some compare treated and untreated groups at the end of an experiment. That distinction matters: a higher final value than a control is not always an increase from the treated subject’s own starting value.

Running farther and keeping muscle are separate outcomes

The treadmill result describes sustained performance. Running twice as long means a 100% increase in time relative to the comparison group. Running 2.16 times as far means a 116% increase in distance. These percentages are mathematical restatements of the reported animal comparison, rather than an estimate for human runners.

The muscle-loss experiment asks a different question. If the healthy comparison value is represented as 100, a 15% loss leaves about 85, while a 5% loss leaves about 95. The treated group retained more tissue. That does not mean it gained 10% new muscle above its original healthy level.

Both results are relevant to physical function, but neither should be converted into an estimated increase in a person’s one-repetition maximum or a promised amount of muscle gain. Training status and the outcome being tested matter as much as the headline percentage.

A separate 2026 mouse study examined cancer-associated wasting. Quadriceps mass was approximately 12% higher with MOTS-C than in tumor-bearing vehicle controls, while total body-weight and fat loss were not prevented. Other muscle and function measurements showed mixed effects. [5]

This is a useful example of a selective result: one tissue can be partly protected while the whole-body outcome remains unchanged. It is evidence about a disease model, rather than a healthy-person muscle-building program.

Weight loss, body fat and visible transformations

A dependable human “before and after” weight-loss amount is not available for these MOTS-C formats. The current native-peptide trial has no posted results, and the established animal literature does not provide a valid conversion into pounds lost by a person. [6]

A body photograph can show appearance, but it cannot separate changes in fat, muscle, posture, lighting or short-term fluid balance. Even an authentic photograph does not isolate a peptide’s contribution when the person also changed training, diet or other treatments.

That makes a numeric promise such as “a certain number of pounds in four weeks” more specific than the evidence allows. A more informative claim would identify the measured tissue, the comparison group and the average change. The mouse muscle-preservation results above do that; an unlabeled transformation does not.

There is also a difference between preventing gain and producing loss. Starting an intervention at the same time as a weight-promoting experimental diet addresses a different question from reversing established obesity. Treating the two as equivalent exaggerates what the experiment demonstrates.

The four-week human results often confused with MOTS-C

CB4211 is a modified analog of MOTS-C, and its human results belong to CB4211. A small phase 1b study reported exploratory outcomes in 11 active-treatment and nine placebo participants with obesity and fatty liver disease. The treatment period lasted four weeks, with participants staying in a clinical study unit. [7]

The sponsor reported statistically significant between-group differences for these exploratory markers. Both groups also reduced liver fat, and the body-weight finding was described as a trend. The study’s main purpose was safety and tolerability. [7]

These are biomarker changes in a specific population, not evidence that native MOTS-C reduces human body weight by the same percentages. A lower liver enzyme value does not itself state how much liver fat, total fat or body weight changed.

The analogy is useful for understanding why mitochondrial peptides entered clinical research. It does not make the analog’s tested regimen or outcomes interchangeable with a 40 mg MOTS-C vial or a 30 mg MOTS-C pen.

The 12-week native MOTS-C trial

MOTS-MET is designed to test insulin sensitivity in adults with prediabetes and overweight or obesity. ClinicalTrials.gov lists NCT07505745 as a randomized, placebo-controlled study with an estimated 120 participants and 12 weeks of daily subcutaneous administration. Safety follow-up extends to week 16. [6]

The registry names an oral-glucose-tolerance-test measure of insulin sensitivity as a primary outcome and includes glucose-control measurements such as HbA1c. When checked on November 7, 2026, the record was recruiting and had no posted results. Its planned primary completion was February 2027. [6]

A planned endpoint is the question investigators intend to answer. It is not a result. The 12-week duration describes the study design; it does not mean benefit begins at week 12 or that everyone needs a course of that length.

Do the vial and pen change the result timeline?

The vial contains 40 mg of powder; the pen contains 30 mg in 3 mL at 10 mg/mL. Total content and concentration help with product comparisons, but they do not establish onset or duration of benefit. [8]

A prefilled format can simplify preparation. It does not, by itself, demonstrate faster tissue delivery, stronger effects or a longer-lasting response. Likewise, having one-third more total labelled peptide in the vial does not predict one-third more benefit.

For the practical differences, see the vial and pen comparison. For the measurements behind the labels, see the dosage and concentration guide. The benefits article explains how endurance, glucose handling and muscle preservation fit together.